These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26850375)

  • 1. Strategies in functional proteomics: Unveiling the pathways to precision oncology.
    Favicchio R; Thepaut C; Zhang H; Arends R; Stebbing J; Giamas G
    Cancer Lett; 2016 Nov; 382(1):86-94. PubMed ID: 26850375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications.
    Jimenez CR; Verheul HM
    Am Soc Clin Oncol Educ Book; 2014; ():e504-10. PubMed ID: 24857147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Giving Up on Precision Oncology? Not So Fast!
    Warner JL
    Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
    [No Abstract]   [Full Text] [Related]  

  • 4. Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine.
    Eke I; Makinde AY; Aryankalayil MJ; Ahmed MM; Coleman CN
    Cancer Lett; 2016 Nov; 382(1):118-126. PubMed ID: 26828133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation.
    Artemov A; Aliper A; Korzinkin M; Lezhnina K; Jellen L; Zhukov N; Roumiantsev S; Gaifullin N; Zhavoronkov A; Borisov N; Buzdin A
    Oncotarget; 2015 Oct; 6(30):29347-56. PubMed ID: 26320181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Future of Precision Oncology for the Treatment of Solid Tumors.
    Klute KA
    Clin Pharmacol Ther; 2020 Sep; 108(3):416-418. PubMed ID: 31983061
    [No Abstract]   [Full Text] [Related]  

  • 7. Preface on application of omics technologies in cancer biology and therapy.
    Georgakilas AG
    Cancer Lett; 2016 Nov; 382(1):A1. PubMed ID: 27765153
    [No Abstract]   [Full Text] [Related]  

  • 8. Oncoproteomics: Trials and tribulations.
    Zhou L; Li Q; Wang J; Huang C; Nice EC
    Proteomics Clin Appl; 2016 Apr; 10(4):516-31. PubMed ID: 26518147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-Based Development and Clinical Use of Precision Oncology Therapeutics.
    Comment LA; Ward AF; Schrock AB; Fabrizio D; Venstrom JM; Hegde PS; Alexander BM
    Clin Pharmacol Ther; 2020 Sep; 108(3):440-443. PubMed ID: 32744335
    [No Abstract]   [Full Text] [Related]  

  • 10. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precision cancer medicine: the future is now, only better.
    Tsimberidou AM; Eggermont AM; Schilsky RL
    Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathology in therapeutics: where are we now, and where are we going?
    Harrison DJ; Faratian D
    Curr Drug Targets; 2012 Nov; 13(12):1473-4. PubMed ID: 22974390
    [No Abstract]   [Full Text] [Related]  

  • 13. Cancer biomarkers: selecting the right drug for the right patient.
    Kelloff GJ; Sigman CC
    Nat Rev Drug Discov; 2012 Feb; 11(3):201-14. PubMed ID: 22322254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticipating designer drug-resistant cancer cells.
    Frangione ML; Lockhart JH; Morton DT; Pava LM; Blanck G
    Drug Discov Today; 2015 Jul; 20(7):790-3. PubMed ID: 25697478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug sensitivity testing platforms for gastric cancer diagnostics.
    Lau V; Wong AL; Ng C; Mok Y; Lakshmanan M; Yan B
    J Clin Pathol; 2016 Feb; 69(2):93-6. PubMed ID: 26567318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature.
    Poornima P; Kumar JD; Zhao Q; Blunder M; Efferth T
    Pharmacol Res; 2016 Sep; 111():290-302. PubMed ID: 27329331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Individualization of anticancer therapy; molecular targets of novel drugs in oncology].
    Regulska K; Stanisz B; Regulski M
    Postepy Hig Med Dosw (Online); 2012 Nov; 66():855-67. PubMed ID: 23175342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivering on the promise of precision cancer medicine.
    Berger MF; Van Allen EM
    Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
    [No Abstract]   [Full Text] [Related]  

  • 20. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics.
    Wijdeven RH; Pang B; Assaraf YG; Neefjes J
    Drug Resist Updat; 2016 Sep; 28():65-81. PubMed ID: 27620955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.